Does Aetna Cover Zepbound and Wegovy? It Depends on Your Aetna Drug List

Aetna covers Wegovy for weight loss on its main commercial drug lists, and since October 1, 2026 it covers Zepbound on more of them. On that date Zepbound was added to the Aetna Standard Plan and High Value formularies, and Aetna’s October 2026 list for its Advanced Control Plan names Zepbound as a preferred drug.^[1][3][4] One list still lagged: the Standard Control Plan’s July 2026 exclusion list kept Zepbound off and pointed members to Wegovy.^[5] Two conditions sit above all of this. Your employer has to choose to cover weight-loss drugs, which Aetna calls a customization the employer makes, and Aetna requires precertification before it pays.^[6] For type 2 diabetes, Aetna pays for Mounjaro and Ozempic under a separate prior authorization.^[2][10]

Which Aetna drug list you are on decides the answer

Aetna does not run one formulary. It publishes several commercial drug lists, and an employer or plan picks one. The name usually appears on your member ID card or in your plan’s drug guide. Here is where the two weight-loss drugs stood in the most recent version of each list we read.

The January 2026 Standard Plan guide shows how things looked before the change: Zepbound sat on the exclusion page, and the covered antiobesity drugs were orlistat, Qsymia, Saxenda and Wegovy.^[2] The October update reversed that for Zepbound and also moved Lilly’s pill, Foundayo, from non-preferred to preferred.^[1] If your plan uses the Standard Control list, check whether a later version has replaced the July one before assuming Zepbound is still excluded.

The timing is not a coincidence. Aetna’s pharmacy benefits are run by CVS Caremark, its sister company inside CVS Health.^[6] Caremark dropped Zepbound from its template formularies in July 2025 and added it back on October 1, 2026; our article on CVS Caremark and Zepbound covers that history.

Your employer chooses whether weight-loss drugs are covered

A drug on the formulary is not the same as a drug covered for you. Aetna tells employers they “can choose to customize your benefits to include or exclude GLP‑1 drug coverage for weight management.”^[6] The drug guide repeats the point from the member side: your plan may not cover weight-loss drugs at all.^[2] When an employer has excluded the category, a precertification request for weight loss fails no matter how well it is documented, because the benefit is not there.

So start with two questions to your HR or benefits office: does our plan cover GLP‑1 drugs for weight management, and which Aetna formulary do we use? Our employer coverage checker lists the questions that get a useful answer, and our guide to getting a GLP‑1 covered explains the difference between an exclusion and a denial.

Aetna’s precertification criteria for weight loss

Aetna’s Wegovy policy, revised August 20, 2026, sets out what a prescriber has to document for an adult. The most recent Zepbound policy Aetna had published, dated April 2025, uses the same weight-loss criteria word for word.^[7][8]

• Age 18 or older. Wegovy injection also has a separate pathway for ages 12 to 17.^[7]
• Six months in a weight-management program first. The patient must have taken part in a comprehensive program covering behavior change, a reduced-calorie diet and more physical activity, with follow-up for at least six months before drug therapy starts. That is longer than some other insurers ask for, so keep the records.^[7]
• A BMI of at least 30, or at least 27 when the patient also has hypertension, type 2 diabetes, abnormal cholesterol or another illness tied to weight. If you are switching from another weight-loss drug, the BMI that counts is the one from before you started any drug.^[7]
• Eight months, then a check. The first approval lasts eight months. Renewal, for 12 months at a time, needs at least three months on a stable maintenance dose and a loss of at least 5% of starting weight, or a 5% loss that has been kept off.^[7]

If a request comes back denied, the notice will say why, and our guide to prior authorization and appeals covers the deadlines that apply.

One detail matters for anyone buying Zepbound vials. Aetna’s Zepbound policies exclude the vials sold through Lilly’s own LillyDirect program from their scope, so a vial bought there is a cash purchase outside your Aetna pharmacy benefit.^[8]

Heart disease, fatty liver and sleep apnea

Wegovy and Zepbound each carry FDA approvals beyond weight loss, and Aetna reviews those uses under their own criteria. Whether a plan that excludes weight-loss drugs still pays for these uses depends on how the plan defines the exclusion, so ask the question by name.

Wegovy to lower the risk of heart attack and stroke

Wegovy’s label includes a heart indication: for people who already have cardiovascular disease and carry excess weight, it lowers the chance of a heart attack, a stroke or death from heart disease.^[13] The evidence is the SELECT trial, which enrolled 17,604 people without diabetes. Over the trial, 6.5% of those on semaglutide and 8.0% of those on placebo had one of those three events, a 20% lower risk.^[14] Aetna’s criteria for this use ask for a prior heart attack, a prior stroke, symptomatic peripheral artery disease or a past revascularization procedure, a BMI of 27 or more, and current standard heart treatment unless there is a reason not to use it.^[7] People with type 2 diabetes are sent to Ozempic for the same purpose instead.^[7]

Wegovy for MASH, the inflammatory form of fatty liver disease

Aetna covers Wegovy injection for MASH with moderate to advanced fibrosis (stage F2 or F3) when a gastroenterologist or liver specialist is involved and the fibrosis is confirmed by elastography or an earlier biopsy. The higher-dose Wegovy HD and the Wegovy pill are not eligible for this use.^[7] Our article on GLP‑1 drugs and fatty liver covers the trial that led to the approval.

Zepbound for obstructive sleep apnea

Of these two drugs, only Zepbound has an FDA sleep apnea approval, which covers obstructive apnea of moderate or greater severity in people who have obesity.^[12] Aetna’s criteria ask for an apnea-hypopnea index of at least 15 events an hour on a lab sleep study or a home test, and a current BMI of 30 or more.^[8] For someone with diagnosed sleep apnea this is a request built on a different diagnosis, which can matter on a plan that limits weight-loss coverage. Our article on Zepbound for sleep apnea covers what the trials found.

Mounjaro and Ozempic for type 2 diabetes

Both diabetes drugs are on the preferred list in Aetna’s 2026 Standard Plan guide.^[2] Aetna’s diabetes policy, last updated March 18, 2026, asks for proof of type 2 diabetes, such as an A1C of 6.5% or more or a qualifying glucose test. It also asks for one more reason to use the drug: metformin did not work, could not be tolerated or cannot be used; the patient needs combination therapy with an A1C of 7.5% or higher; or the patient has fatty liver disease, heart disease or kidney disease that fits the specific drug.^[10] Neither Mounjaro nor Ozempic is approved for weight loss, and a request that does not show diabetes will not meet this policy.

Mounjaro has also served as Aetna’s fallback when Zepbound was excluded. Aetna’s July 2025 Zepbound exception policy pointed prescribers first to Wegovy, then to brand Mounjaro for patients who had an inadequate response, side effects they could not tolerate, or a reason they could not take Wegovy.^[9] That policy was written for formularies that excluded Zepbound, and with Zepbound back on several lists it may since have been revised, so ask whether it still applies to your plan.

Aetna Medicare members

For Aetna Medicare members, weight-loss coverage comes from a federal program rather than the Aetna plan. The Medicare GLP‑1 Bridge started on July 1, 2026 and is scheduled to end on December 31, 2027; members who qualify pay $50 a month for Foundayo, the Wegovy injection or tablets, or the Zepbound KwikPen. Aetna points out that the program is run by Medicare, not by Aetna, and that Aetna Medicare does not approve Bridge requests.^[11] Our Medicare GLP‑1 Bridge guide covers who qualifies and how a prescriber applies.

If your Aetna plan does not cover it

1. Read the reason on the denial. “Benefit excluded” means your employer left the category out, and only a plan change fixes that. “Criteria not met” means the paperwork fell short, and a resubmission with the missing records often succeeds.
2. Ask for a formulary exception when the drug is excluded from your list but the category is covered. The strongest requests document what happened on the covered alternative, usually Wegovy, with dates and doses.
3. Check the other diagnoses. Sleep apnea, a past heart attack or stroke, and MASH each have their own criteria.
4. Ask again at open enrollment. Employers revisit these choices every year, and Aetna’s lists change every quarter.

Paying cash is the last option. Lilly sells the Zepbound KwikPen and vial from $299 a month at the starting dose and $399 at 5 mg, with higher doses at $449 when refilled on time.^[15] Novo Nordisk sells Wegovy pens for $349 a month at most doses after an introductory offer, and its savings card can bring an insured fill to as little as $25 when your plan covers the drug.^[16] Our ranking of the cheapest GLP‑1 without insurance compares every route.